Opinion

Video

The Role for PSMA-PET Imaging in Active Surveillance

Author(s):

Brian Helfand, MD, PhD,Gordon A. Brown, DO

Focusing on active surveillance of patients with prostate cancer, discussion centers around the role of PSMA-PET imaging and the implications of negative scans.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Advances across urology: Insights from UNC faculty
      Advances across urology: Insights from UNC faculty
      Timothy McClure, MD, on patient selection for focal therapy
      Timothy McClure, MD, on patient selection for focal therapy
      2 experts in this video
      Shared Decision-Making and Treatment Adherence
      Related Content
      3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      August 18th 2025

      PSMA PET/CT prior to salvage radiotherapy may improve overall survival

      Hannah Clarke
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      August 18th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      FDA grants de novo authorization to ArteraAI Prostate
      August 18th 2025

      FDA grants de novo authorization to ArteraAI Prostate

      Hannah Clarke Benjamin P. Saylor
      Dr. Murphy on increasing diversity in cancer clinical trials
      August 18th 2025

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer
      August 18th 2025

      FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer

      Hannah Clarke
      FDA greenlights phase 1 trial of NSD2 inhibitor in mCRPC
      August 18th 2025

      FDA greenlights phase 1 trial of NSD2 inhibitor in mCRPC

      Hannah Clarke
      © 2025 MJH Life Sciences

      All rights reserved.